CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it has completed submission of all the major sections of CMC modules to FDA, some remaining supporting documentation will be submitted under Regional Information before the end of this week.

Speaking of peer review, the first sentence of the PR is a run on. Couldn't PR their way out of a paper bag. Big Pharma rests easy for a while longer.